Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome

키워드

참고문헌 (96)

1. Moake JL, "Thrombotic microangiopathies", N Engl J Med, 347, pp.589~600 (2002)
2. Gasser C, "Hemolytic-uremic syndrome : bilateral necrosis of the renal cortex in acute acquired hemolytic anemia", Schweiz Med Wochenschr, 85, pp.905~909 (1955)
3. Moake JL, "Unusually large plasma factor VIII : von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura", N Engl J Med, 307, pp.1432~1435 (1982)
4. Karmali MA, "The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli", J Infect Dis, 151, pp.775~782 (1985)
5. Mele C, "Hemolytic uremic syndrome", Semin Immunopathol, 36, pp.399~420 (2014)
6. De S, "Severe atypical HUS caused by CFH S1191L : case presentation and review of treatment options", Pediatr Nephrol, 25, pp.97~104 (2010)
7. Rosales A, "Thrombotic microangiopathy : atypical HUS : current diagnostic and therapeutic approaches", Nat Rev Nephrol, 6, pp.504~506 (2010)
8. Salant DJ, "Targeting complement C5 in atypical hemolytic uremic syndrome", J Am Soc Nephrol, 22, pp.7~9 (2011)
9. 정해일, "Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea", Journal of Korean Medical Science, 31(10), pp.1516~1528 (2016), 대한의학회
10. George JN, "Syndromes of thrombotic microangiopathy", N Engl J Med, 371, pp.654~666 (2014)
11. Kato H, "Clinical guides for atypical hemolytic uremic syndrome in Japan", Clin Exp Nephrol, 20, pp.536~543 (2016)
12. Sawai T, "Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the Joint Committee of the Japanese Society of Nephrology and the Japan Pediatric Society", Clin Exp Nephrol, 18, pp.4~9 (2014)
13. Laurence J, "Atypical hemolytic uremic syndrome(aHUS) : essential aspects of an accurate diagnosis", Clin Adv Hematol Oncol, 14(Suppl 11), pp.2~15 (2016)
14. Claes KJ, "Belgian consensus statement on the diagnosis and management of patients with atypical hemolytic uremic syndrome", Acta Clin Belg, 73, pp.80~89 (2018)
15. Legendre CM, "Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome", N Engl J Med, 368, pp.2169~2181 (2013)
16. Noris M, "Atypical hemolytic-uremic syndrome", N Engl J Med, 361, pp.1676~1687 (2009)
17. Goldberg RJ, "The role of endothelial cell injury in thrombotic microangiopathy", Am J Kidney Dis, 56, pp.1168~1174 (2010)
18. Goodship TH, "Atypical hemolytic uremic syndrome and C3 glomerulopathy:conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference", Kidney Int, 91, pp.539~551 (2017)
19. Lusco MA, "AJKD atlas of renal pathology : thrombotic microangiopathy", Am J Kidney Dis, 68, pp.e33~e34 (2016)
20. Goyal A, "Acute Kidney Injury (Acute Renal Failure)" (2019), Stat-Pearls Publishing
21. Kang E, "Clinical dissection of thrombotic microangiopathy", Ann Hematol, 96, pp.1715~1726 (2017)
22. Asif A, "Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions:case reports and a review of the evidence for treatment with eculizumab", J Nephrol, 30, pp.347~362 (2017)
23. Noris M, "Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype", Clin J Am Soc Nephrol, 5, pp.1844~1859 (2010)
24. Fakhouri F, "Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations", J Am Soc Nephrol, 21, pp.859~867 (2010)
25. Brocklebank V, "Thrombotic microangiopathy and the kidney", Clin J Am Soc Nephrol, 13, pp.300~317 (2018)
26. Timmermans SAMEG, "Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities", Kidney Int, 91, pp.1420~1425 (2017)
27. Zhang B, "Renal thrombotic microangiopathies induced by severe hypertension", Hypertens Res, 31, pp.479~483 (2008)
28. Reynolds JC, "Thrombotic microangiopathy after renal transplantation in the United States", Am J Kidney Dis, 42, pp.1058~1068 (2003)
29. Karthikeyan V, "Outcome of plasma exchange therapy in thrombotic microangiopathy after renal transplantation", Am J Transplant, 3, pp.1289~1294 (2003)
30. Zarifian A, "Cyclosporine-associated thrombotic microangiopathy in renal allografts", Kidney Int, 55, pp.2457~2466 (1999)
31. Abbas F, "Thrombotic microangiopathy after renal transplantation : current insights in de novo and recurrent disease", World J Transplant, 8, pp.122~141 (2018)
32. Garg N, "De novo thrombotic microangiopathy after kidney transplantation", Transplant Rev(Orlando), 32, pp.58~68 (2018)
33. Noris M, "Thrombotic microangiopathy after kidney transplantation", Am J Transplant, 10, pp.1517~1523 (2010)
34. Zuber J, "Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation", Transplant Rev(Orlando), 27, pp.117~125 (2013)
35. Bresin E, "Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype", J Am Soc Nephrol, 24, pp.475~486 (2013)
36. Campistol JM, "An update for atypical haemolytic uraemic syndrome : diagnosis and treatment. A consensus document", Nefrologia, 35, pp.421~447 (2015)
37. Nadasdy T, "Thrombotic microangiopathy in renal allografts : the diagnostic challenge", Curr Opin Organ Transplant, 19, pp.283~292 (2014)
38. Ponticelli C, "Thrombotic microangiopathy after kidney transplantation", Transpl Int, 19, pp.789~794 (2006)
39. Verbiest A, "De novo thrombotic microangiopathy after non-renal solid organ transplantation", Blood Rev, 28, pp.269~279 (2014)
40. Chapin J, "Hematopoietic transplant-associated thrombotic microangiopathy : case report and review of diagnosis and treatments", Clin Adv Hematol Oncol, 12, pp.565~573 (2014)
41. Dhakal P, "Is complement blockade an acceptable therapeutic strategy for hematopoietic cell transplant-associated thrombotic microangiopathy", Bone Marrow Transplant, 52, pp.352~356 (2017)
42. Jodele S, "The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy", Blood, 127, pp.989~996 (2016)
43. Al-Nouri ZL, "Drug-induced thrombotic microangiopathy : a systematic review of published reports", Blood, 125, pp.616~618 (2015)
44. Bollee G, "Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib", Nephrol Dial Transplant, 24, pp.682~685 (2009)
45. El-Ghazal R, "Mitomycin : C-induced thrombotic thrombocytopenic purpura", hemolytic uremic syndrome : cumulative toxicity of an old drug in a new era, 2011, pp.10, 142~145
46. Kiuru M, "Cutaneous thrombogenic vasculopathy associated with bevacizumab therapy", Dermatol Online J, 20, pp.pii13030~ (2014)
47. 이혜원, "Gemcitabine-Induced Hemolytic Uremic Syndrome in Pancreatic Cancer: A Case Report and Review of the Literature", Gut and Liver, 8(1), pp.109~112 (2014), 거트앤리버 소화기연관학회협의회
48. Racca P, "Hemolytic uremic syndrome induced by infusion of oxaliplatin : a case report", Tumori, 97, pp.31e~33e (2011)
49. Said T, "Posttransplantation calcineurin inhibitor-induced hemolytic uremic syndrome : single-center experience", Transplant Proc, 42, pp.814~816 (2010)
50. Gottschall JL, "Quinine-induced immune thrombocytopenia associated with hemolytic uremic syndrome : a new clinical entity", Blood, 77, pp.306~310 (1991)
51. Kavanagh D, "Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature", Blood, 128, pp.2824~2833 (2016)
52. Eremina V, "VEGF inhibition and renal thrombotic microangiopathy", N Engl J Med, 358, pp.1129~1136 (2008)
53. El-Husseini A, "Thrombotic microangiopathy in systemic lupus erythematosus : efficacy of eculizumab", Am J Kidney Dis, 65, pp.127~130 (2015)
54. Thomas CP, "Eculizumab for rescue of thrombotic microangiopathy in PM-Scl antibody-positive autoimmune overlap syndrome", Clin Kidney J, 8, pp.698~701 (2015)
55. Manenti L, "Atypical haemolytic uraemic syndrome with underlying glomerulopathies : a case series and a review of the literature", Nephrol Dial Transplant, 28, pp.2246~2259 (2013)
56. Cavero T, "Eculizumab in secondary atypical haemolytic uraemic syndrome", Nephrol Dial Transplant, 32, pp.466~474 (2017)
57. Lupu F, "Crosstalk between the coagulation and complement systems in sepsis", Thromb Res, 133(Suppl 1), pp.S28~S31 (2014)
58. Wada H, "Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy", Thromb J, 16, pp.14~ (2018)
59. Lopes da Silva R, "Viral-associated thrombotic microangiopathies", Hematol Oncol Stem Cell Ther, 4, pp.51~59 (2011)
60. Narayanan P, "Haemolytic uraemic syndrome associated with Pseudomonas aeruginosa sepsis", J Med Microbiol, 62, pp.1760~1762 (2013)
61. Java A, "Cytomegalovirus-induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab : case report and review of the literature", Transpl Int, 28, pp.1121~1125 (2015)
62. Ward PA, "The dark side of C5a in sepsis", Nat Rev Immunol, 4, pp.133~142 (2004)
63. Galic S, "A case report of a child with sepsis induced multiorgan failure and massive complement consumption treated with a short course of eculizumab: a case of crosstalk between coagulation and complement?", Medicine (Baltimore), 98, pp.e14105~ (2019)
64. Noris M, "GeneReviews" (1993), University of Washington
65. Kavanagh D, "Atypical hemolytic uremic syndrome", Semin Nephrol, 33, pp.508~530 (2013)
66. Nester CM, "Atypical aHUS : state of the art", Mol Immunol, 67, pp.31~42 (2015)
67. Jokiranta TS, "HUS and atypical HUS", Blood, 129, pp.2847~2856 (2017)
68. Richards S, "Standards and guidelines for the interpretation of sequence variants : a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology", Genet Med, 17, pp.405~424 (2015)
69. Marinozzi MC, "Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign", J Am Soc Nephrol, 25, pp.2053~2065 (2014)
70. Jozsi M, "Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1", CFHR3 deficiency, 2008, pp.111, 1512~1514
71. Loirat C, "An international consensus approach to the management of atypical hemolytic uremic syndrome in children", Pediatr Nephrol, 31, pp.15~39 (2016)
72. Venables JP, "Atypical haemolytic uraemic syndrome associated with a hybrid complement gene", PLoS Med, 3, pp.e431~ (2006)
73. Lee JM, "Atypical hemolytic uremic syndrome : Korean pediatric series", Pediatr Int, 57, pp.431~438 (2015)
74. Yun JW, "Frequent thrombomodulin (THBD) variants in Korean adult patients with atypical hemolytic uremic syndrome", The 36th Conference of the Korean Society on Thrombosis and Hemostasis, pp.556~557 (2019), Korean Society on Thrombosis and Hemostasis
75. Schwartz J, "Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American Society for Apheresis : the seventh special issue", J Clin Apher, 31, pp.149~162 (2016)
76. Loirat C, "Plasmatherapy in atypical hemolytic uremic syndrome", Semin Thromb Hemost, 36, pp.673~681 (2010)
77. Schwartz J, "Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis : the sixth special issue", J Clin Apher, 28, pp.145~284 (2013)
78. Ariceta G, "Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome", Pediatr Nephrol, 24, pp.687~696 (2009)
79. Loirat C, "Atypical hemolytic uremic syndrome", Orphanet J Rare Dis, 6, pp.60~ (2011)
80. Zuber J, "Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies", Nat Rev Nephrol, 8, pp.643~657 (2012)
81. Clark WF, "Plasmapheresis for the treatment of kidney diseases", Kidney Int, 90, pp.974~984 (2016)
82. Azoulay E, "Expert statements on the standard of care in critically ill adult patients with atypical hemolytic uremic syndrome", Chest, 152, pp.424~434 (2017)
83. Walle JV, "Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment", J Nephrol, 30, pp.127~134 (2017)
84. Cataland SR, "How I treat : the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome", Blood, 123, pp.2478~2484 (2014)
85. "ULTOMIRIS® (ravulizumab-cwvz) injection, for intravenous use" (2019)[URL]
86. Bresin E, "Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome : prognostic significance of genetic background", Clin J Am Soc Nephrol, 1, pp.88~99 (2006)
87. Stegall MD, "Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients", Am J Transplant, 11, pp.2405~2413 (2011)
88. Zuber J, "Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation", Am J Transplant, 12, pp.3337~3354 (2012)
89. Gonzalez Suarez ML, "Outcomes of kidney transplant patients with atypical hemolytic uremic syndrome treated with eculizumab : a systematic review and meta-analysis", J Clin Med, 8, pp.E919~ (2019)
90. Menne J, "Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study", BMC Nephrol, 20, pp.125~ (2019)
91. Siedlecki AM, "Eculizumab use for kidney transplantation in patients with a diagnosis of atypical hemolytic uremic syndrome", Kidney Int Rep, 4, pp.434~446 (2018)
92. Saland JM, "Liver-kidney transplantation to cure atypical hemolytic uremic syndrome", J Am Soc Nephrol, 20, pp.940~949 (2009)
93. Satoskar AA, "De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection", Am J Transplant, 10, pp.1804~1811 (2010)
94. Djamali A, "Diagnosis and management of antibody-mediated rejection : current status and novel approaches", Am J Transplant, 14, pp.255~271 (2014)
95. Le Quintrec M, "Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome", Am J Transplant, 13, pp.663~675 (2013)
96. 김세진, "Kidney Transplantation in Patients with Atypical Hemolytic Uremic Syndrome due to Complement Factor H Deficiency: Impact of Liver Transplantation", Journal of Korean Medical Science, 33(1), pp.41~51 (2018), 대한의학회

관련 논문AI추천